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The report of the ISPOR Real World Data Task Force
[1] is very timely, in that a number of reimbursement
bodies worldwide are now expressing a need for “real-
world” data. With the exception of safety data, the
requirements to collect such data are rarely mandatory,
so discussion needs to take place about precisely what
data are required and who will collect them.
The Task Force report makes a number of impor-
tant contributions. First, it provides some clear deﬁ-
nitions of what constitutes “real-world data” and the
difference between “data” and “evidence.” Second, it
contains helpful characterizations of real-world data,
by type of outcome (e.g., clinical, economic, patient-
reported outcomes), by hierarchy of evidence (e.g.,
randomized controlled trial, observational study),
and by source of data (e.g., supplements to trials,
registries). Third, it makes a sound intellectual case
for the need for real-world data (see the section of
the report on “Recognizing the importance of RW
data”).
Nevertheless, as the report progresses, it becomes
clear that several methodological and practical ques-
tions need to be answered before we can make much
progress in the collection and use of real-world data.
Two statements in the report point to this need. First,
in the section on “The level of evidence required
depends on the circumstance,” the authors state that
“Decisions typically rely on multiple sources, and are
best thought of as conditional––to be revisited as
additional evidence is generated.” Then, in the “Con-
clusions,” they state that “It is critical that policy
makers recognize the beneﬁts, limitations, and meth-
odological challenges in using RW data, and the need
to carefully consider the costs and beneﬁts of different
forms of data collection in different situations.” The
danger, in my view, is that these issues will not be
adequately debated. Either a requirement for real-
world data will be added (without much thought) to
the existing list of data requirements, or there will
remain a lack of guidance on which data to collect in
a given situation.
Therefore, having made the intellectual case for the
collection of real-world data, there is an urgent need for
a discussion of some of the detail. First, regarding
methods, which types of data can be considered accept-
able forms of evidence for answering a particular ques-
tion? For example, can the comparative effectiveness of
therapies only be determined through an RCT, or can
it be determined through an observational study, if
accompanied by an appropriate analytic strategy?
Second, regarding the practical issues, how can appro-
priate incentives be given for the collection of real-
world data? Are there occasions where it should be
mademandatory (beyond the collection of safety data)?
Alternatively, can incentives be provided by a commit-
ment, by decision-makers, to revisit certain decisions if
certain categories of data are collected? Would the
collection of real-world data be best integrated with
formal risk-sharing schemes, where these exist?
In my view, the collection of real-world data repre-
sents an important way forward. However, for it to
proceed in a comprehensive fashion, we need a reality
check on several important methodological and prac-
tical issues. Detailed methodological guidance for the
collection of real-world data needs to be produced, to
mirror that we have for modeling studies and “piggy-
back” economic evaluations undertaken alongside
clinical trials. Also, reimbursement agencies need to
engage in more discussions about the types of data
required and the decisions that will result.
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